Arthritis Patients Should Not Pause Meds for COVID Vaccine

A multicenter study finds that holding immunomodulatory therapy increases flare risk without improving vaccine antibody response.

Updated on Oct. 28, 2026 in Arthritis

Arthritis Patients Should Not Pause Meds for COVID Vaccine

Live Poll

Is it worth pausing your regular prescribed medications to potentially improve your response to a vaccine?

A clinical trial published in May 2024 concludes that patients with inflammatory arthritis should not pause their prescribed biologics or JAK inhibitors after receiving a COVID-19 vaccine. Researchers found that pausing therapy does not boost antibody response but does significantly raise the risk of disease flares.

Why it matters

The findings challenge previous assumptions that suspending immunosuppressive treatments might improve vaccine efficacy in patients with chronic inflammatory conditions. By maintaining their medication schedule, patients can avoid unnecessary disease progression without compromising their protective immune response to the vaccine.

The study included 840 patients and observed an antibody GMFR ratio of 0.96 between the hold and continue groups. Patients using JAK inhibitors saw a 12% risk difference for worsening disease symptoms when treatments were temporarily paused.

The players

University of Alabama at Birmingham

This public research university houses the medical researchers who conducted the multicenter trial to evaluate medication protocols for arthritis patients.

The details

The randomized study tracked 319 patients who continued their therapy and 336 patients who paused their medication for two weeks following a supplemental COVID-19 vaccine. While all participants showed increased antibody levels by the six-week mark, those who held their medication were more than twice as likely to experience an inflammatory arthritis flare.

November 2021 to May 2024 marked the enrollment and vaccine administration phase.
Patients in the study paused their immunomodulatory therapy for a duration of 2 weeks.
Researchers conducted the primary outcome measurement during a week 6 follow-up visit.

The Big Picture

This research provides a necessary update to the clinical protocols for immunomodulatory therapy in rheumatic disease, which have been subject to varying guidance during the pandemic. It marks a shift away from precautionary treatment pauses that were previously thought to benefit patient immune response.

Patients with inflammatory arthritis should consult their rheumatologists before making any changes to their prescribed medication schedule, especially around vaccine doses. This study suggests that maintaining your standard regimen is likely the safer choice for preventing painful disease flares.

The takeaway

Maintaining a consistent medication schedule remains critical for patients with inflammatory arthritis, even when receiving supplemental vaccinations. Data suggests that the risk of a disease flare far outweighs any theoretical benefit to vaccine-induced antibody levels.